Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose ...

FDA Drug Recall #D-0398-2026 — Class II — February 4, 2026

Recall Summary

Recall Number D-0398-2026
Classification Class II — Moderate risk
Date Initiated February 4, 2026
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm SOMERSET THERAPEUTICS LLC
Location Somerset, NJ
Product Type Drugs
Quantity 62190 vials

Product Description

Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873, NDC carton: 70069-025-10; NDC vial: 70069-025-01

Reason for Recall

Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lot #: A240421, Exp 07/31/2026

Other Recalls from SOMERSET THERAPEUTICS LLC

Recall # Classification Product Date
D-0238-2026 Class III Cisatracurium Besylate Injection USP, 20 mg/10 ... Nov 26, 2025
D-0237-2026 Class III Cisatracurium Besylate Injection USP, 200mg/20m... Nov 26, 2025
D-0236-2026 Class III Cisatracurium Besylate Injection USP, 10 mg/5 m... Nov 26, 2025
D-0169-2025 Class III Atropine Sulfate Ophthalmic Solution, USP 1%, 5... Dec 16, 2024
D-0506-2024 Class II Haloperidol decanoate Injection 50mg/mL, packag... Apr 24, 2024

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.